Search research articles
Contact Us
Filters
Showing results (1-10 of 113) with videos related to
Page
of 12
Sort By:
Journal of Cardiovascular Risk
|
December 29, 1998
Genetic and molecular markers for vascular disease. Overview
C M Ballantyne
The American Journal of Cardiology
|
November 18, 1998
Low-density lipoproteins and risk for coronary artery disease
C M Ballantyne
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|
June 27, 2000
Statins after cardiac transplantation: which statin, what dose, and how low should we go?
C M Ballantyne
Clinical Cardiology
|
August 15, 2001
Newer risk markers and surrogate endpoints in atherosclerosis management
C M Ballantyne
The American Journal of Medicine
|
July 31, 1998
Current thinking in lipid lowering
C M Ballantyne
The New England Journal of Medicine
|
February 8, 1996
Drugs in cardiac transplantation
C M Ballantyne
The American Journal of Cardiology
|
October 10, 1998
Clinical trial endpoints: angiograms, events, and plaque instability
C M Ballantyne
International Journal of Clinical Practice. Supplement
|
September 26, 2002
Familial hypercholesterolaemia: optimum treatment strategies
C M Ballantyne
The American Journal of Managed Care
|
June 1, 2001
Surrogate endpoints and newer risk markers in atherosclerosis management
C M Ballantyne
Circulation
|
September 26, 2001
September 11, 2001
C M Ballantyne
Page
of 12
Search research articles
Search
Showing results (1-10 of 113) with videos related to
Sort By:
Page
of 12
Journal of Cardiovascular Risk
|
December 29, 1998
Genetic and molecular markers for vascular disease. Overview
C M Ballantyne
The American Journal of Cardiology
|
November 18, 1998
Low-density lipoproteins and risk for coronary artery disease
C M Ballantyne
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|
June 27, 2000
Statins after cardiac transplantation: which statin, what dose, and how low should we go?
C M Ballantyne
Clinical Cardiology
|
August 15, 2001
Newer risk markers and surrogate endpoints in atherosclerosis management
C M Ballantyne
The American Journal of Medicine
|
July 31, 1998
Current thinking in lipid lowering
C M Ballantyne
The New England Journal of Medicine
|
February 8, 1996
Drugs in cardiac transplantation
C M Ballantyne
The American Journal of Cardiology
|
October 10, 1998
Clinical trial endpoints: angiograms, events, and plaque instability
C M Ballantyne
International Journal of Clinical Practice. Supplement
|
September 26, 2002
Familial hypercholesterolaemia: optimum treatment strategies
C M Ballantyne
The American Journal of Managed Care
|
June 1, 2001
Surrogate endpoints and newer risk markers in atherosclerosis management
C M Ballantyne
Circulation
|
September 26, 2001
September 11, 2001
C M Ballantyne
Page
of 12